Recent Post
Conventional methods of dealing with mental health not working
According to the nation’s largest, proactive, online mental health check, conventional approaches to managing mental health are expensive, time-consuming and inaccurate. Australia’s Biggest Mental Health Check-in – an innovative digital public health initiative, in conjunction with Medibio’s world first wearable objective test for the diagnosis of depression and other mental health disorders, designed to measure,…
Read MoreOccupational exposure link to COPD found
According to an Australian study released this week, workers exposed to herbicides in their workplace are more than twice as likely to develop chronic obstructive pulmonary disease (COPD) by the time they reach middle age. For those exposed to pesticides, there is a 74 per cent increased chance of developing COPD. The British Medical Journal…
Read MoreGHPR founder John Seng to be inducted into Hall of Fame
VIVA! Communications is thrilled to see the announcement today that GLOBALHealthPR (GHPR) founder, John Seng, is to be inducted into the National Capital Public Relations (NCPR) Hall of Fame. Seng will be honoured at the Public Relations Society of America’s annual gala in October this year following a decades long career in the industry. Working…
Read MoreAussie biotech appoints American royalty to its Board of Directors
VIVA! Communications are thrilled to be working with Australian medical technology company Medibio as they today (June 4, 2017) announce the appointment of mental health advocate and former U.S. congressman, Patrick J. Kennedy, to their Board of Directors. Patrick J. Kennedy is a former member of the U.S. House of Representatives and America’s leading political…
Read MoreGovernment adds $142 million in medicines to PBS
As of July 1, 2017, the Federal Government has made AUD$142 million in new medicine listings to the Pharmaceutical Benefits Scheme (PBS), in a bid to make more medicines affordable to all Australians. Among the new listings, the PBS will fund access to vorinostat to treat patients living a subtype of blood cancer, non-Hodgkin’s lymphoma called…
Read More